Stock Track | Harrow Health Inc (HROW) Plummets 5.09% as Q3 Earnings Reveal Operational Challenges Despite Record Revenue

Stock Track

2024/11/15

Harrow Health Inc (NASDAQ: HROW) saw its stock plummet 5.09% in Friday's intraday trading session, following the release of its Q3 2024 earnings results. Despite reporting record revenue growth, the company faced several operational challenges that dampened investor sentiment.

While Harrow posted a 44% increase in revenue to $49.3 million, the company experienced a temporary inventory shortage of its key product, VVI, in mid-September, capping its revenue potential for the quarter. Additionally, the strategic 'retina pivot' for its product Ihio led to subdued demand during Q3 as the sales team focused on new sales processes.

Uncertainty surrounding pricing and reimbursement for the relaunched product Tri Essence, as well as the typical summer seasonality impacts on surgical scheduling, also weighed on the company's performance. Although Harrow acknowledged these challenges and outlined contingency plans, investors appeared cautious about the potential implications on future growth.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1165283157"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165283157\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165283157?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165283157","market":"hk","top_or_hot":-1,"title":"Stock Track | Harrow Health Inc (HROW) Plummets 5.09% as Q3 Earnings Reveal Operational Challenges Despite Record Revenue","media":"Stock Track","content":"<p>Harrow Health Inc (NASDAQ: HROW) saw its stock plummet 5.09% in Friday's intraday trading session, following the release of its Q3 2024 earnings results. Despite reporting record revenue growth, the company faced several operational challenges that dampened investor sentiment.</p>\n\n<p>While Harrow posted a 44% increase in revenue to $49.3 million, the company experienced a temporary inventory shortage of its key product, VVI, in mid-September, capping its revenue potential for the quarter. Additionally, the strategic 'retina pivot' for its product Ihio led to subdued demand during Q3 as the sales team focused on new sales processes.</p>\n\n<p>Uncertainty surrounding pricing and reimbursement for the relaunched product Tri Essence, as well as the typical summer seasonality impacts on surgical scheduling, also weighed on the company's performance. Although Harrow acknowledged these challenges and outlined contingency plans, investors appeared cautious about the potential implications on future growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Harrow Health Inc (HROW) Plummets 5.09% as Q3 Earnings Reveal Operational Challenges Despite Record Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Harrow Health Inc (HROW) Plummets 5.09% as Q3 Earnings Reveal Operational Challenges Despite Record Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-15 23:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Harrow Health Inc (NASDAQ: HROW) saw its stock plummet 5.09% in Friday's intraday trading session, following the release of its Q3 2024 earnings results. Despite reporting record revenue growth, the company faced several operational challenges that dampened investor sentiment.</p>\n\n<p>While Harrow posted a 44% increase in revenue to $49.3 million, the company experienced a temporary inventory shortage of its key product, VVI, in mid-September, capping its revenue potential for the quarter. Additionally, the strategic 'retina pivot' for its product Ihio led to subdued demand during Q3 as the sales team focused on new sales processes.</p>\n\n<p>Uncertainty surrounding pricing and reimbursement for the relaunched product Tri Essence, as well as the typical summer seasonality impacts on surgical scheduling, also weighed on the company's performance. Although Harrow acknowledged these challenges and outlined contingency plans, investors appeared cautious about the potential implications on future growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HROW","symbol_name":"Harrow Health Inc","start_time":0,"source_url":"","article_id":"1165283157","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165283157","pubTimestamp":1731682953,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Harrow Health Inc  saw its stock plummet 5.09% in Friday's intraday trading session, following the release of its Q3 2024 earnings results. Despite reporting record revenue growth, the company faced several operational challenges that dampened investor sentiment.While Harrow posted a 44% increase in revenue to $49.3 million, the company experienced a temporary inventory shortage of its key product, VVI, in mid-September, capping its revenue potential for the quarter. Additionally, the strategic ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HROW":"Harrow Health Inc"},"translate_title":"Harrow Health Inc(HROW)股价暴跌5.09%，尽管收入创纪录，但第三季度收益仍显示运营挑战","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1},"content_text":"Harrow Health Inc (NASDAQ: HROW) saw its stock plummet 5.09% in Friday's intraday trading session, following the release of its Q3 2024 earnings results. Despite reporting record revenue growth, the company faced several operational challenges that dampened investor sentiment.\nWhile Harrow posted a 44% increase in revenue to $49.3 million, the company experienced a temporary inventory shortage of its key product, VVI, in mid-September, capping its revenue potential for the quarter. Additionally, the strategic 'retina pivot' for its product Ihio led to subdued demand during Q3 as the sales team focused on new sales processes.\nUncertainty surrounding pricing and reimbursement for the relaunched product Tri Essence, as well as the typical summer seasonality impacts on surgical scheduling, also weighed on the company's performance. Although Harrow acknowledged these challenges and outlined contingency plans, investors appeared cautious about the potential implications on future growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}